Cargando…

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer

HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B subtype of breast cancer. The underlying biological mechanisms that link them are, however, incompletely understood. Here, we evaluated the putative rol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menendez, Javier A., Mehmi, Inderjit, Papadimitropoulou, Adriana, Vander Steen, Travis, Cuyàs, Elisabet, Verdura, Sara, Espinoza, Ingrid, Vellon, Luciano, Atlas, Ella, Lupu, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588883/ https://www.ncbi.nlm.nih.gov/pubmed/33081219 http://dx.doi.org/10.3390/ijms21207661

Ejemplares similares

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α(6)β(1) drives endocrine resistance in breast cancer cells
por: Espinoza, Ingrid, et al.
Publicado: (2022)

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres
por: Menendez, Javier A., et al.
Publicado: (2015)

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells
por: Schroeder, Barbara, et al.
Publicado: (2021)

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells
por: Menendez, Javier A., et al.
Publicado: (2016)

Heregulin, a new regulator of telomere length in human cells
por: Menendez, Javier A., et al.
Publicado: (2015)

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
por: Cuyàs, Elisabet, et al.
Publicado: (2021)

Nutritional Niches of Cancer Therapy-Induced Senescent Cells
por: Llop-Hernández, Àngela, et al.
Publicado: (2022)

Circulating levels of MOTS-c in patients with breast cancer treated with metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

In silico clinical trials for anti-aging therapies
por: Menendez, Javier A., et al.
Publicado: (2019)

Lung Cancer Management with Silibinin: A Historical and Translational Perspective
por: Verdura, Sara, et al.
Publicado: (2021)

Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1
por: Hiscox, S, et al.
Publicado: (2008)

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

γ-Heregulin has no biological significance in primary breast cancer
por: Sánchez-Valdivieso, E A, et al.
Publicado: (2002)

Heregulin Activity Assays for Residual Testing of Cell Therapy Products
por: Monje, Paula V., et al.
Publicado: (2021)

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based “starvation” strategies in BRCA1 carriers
por: Cuyàs, Elisabet, et al.
Publicado: (2016)

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan
por: Hiscox, Stephen, et al.
Publicado: (2012)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022)

Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
por: Mitsui, Keigo, et al.
Publicado: (2014)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer
por: Wu, Minhua, et al.
Publicado: (2021)

Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
por: Menendez, J A, et al.
Publicado: (2017)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

TET2 directs mammary luminal cell differentiation and endocrine response
por: Kim, Mi Ran, et al.
Publicado: (2020)

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021)

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
por: Kang, Jeffrey C, et al.
Publicado: (2014)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

The nutritional phenome of EMT-induced cancer stem-like cells
por: Cuyàs, Elisabet, et al.
Publicado: (2014)

Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pouu5r36qckd339j8lvmk3fhgi